Dempsey Amanda F, Cowan Anne E, Broder Karen R, Kretsinger Katrina, Stokley Shannon, Clark Sarah J
Child Health Evaluation and Research Unit, Department of Pediatrics, University of Michigan, Ann Arbor, MI 48109-5456, USA.
J Adolesc Health. 2009 Apr;44(4):387-93. doi: 10.1016/j.jadohealth.2008.08.019. Epub 2008 Nov 7.
In 2006 the Advisory Committee on Immunization Practices (ACIP) recommended replacement of the adolescent tetanus and diphtheria toxoids (Td) booster with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap). We examined the degree to which pediatricians and family practitioners have adopted this recommendation.
National mail-based survey of a random sample of 725 pediatricians and 725 family practitioners from January through March, 2007.
Overall response rate was 60%. The majority of respondents indicated they routinely recommended Tdap to adolescents at the preferred age for vaccination, 11-12 years old (87%), and also for "catch up" vaccination among adolescents 13-18 years old (89%). In bivariate analyses, pediatrician specialty, specialty society membership, stocking Tdap in the office, and prior experience diagnosing adolescent pertussis were associated with routinely recommending Tdap to adolescents. In multivariable models adjusting for these factors simultaneously, only pediatrician specialty (OR = 4.8, 95% CI = 2.5-9.3) and stocking Tdap in the office (OR = 14.5, 95% CI = 7.5-28.5) remained significantly associated with routine recommendation. Pediatricians were significantly more likely than family practitioners to accept shorter time intervals for administering Tdap following Td vaccination, and to co-administer Tdap with MCV4. Lack of adolescent visits was the most commonly cited major barrier to adolescent Tdap administration.
Based on self report, our results indicate the majority of physicians have adopted recent recommendations from the ACIP to administer Tdap to adolescents. However, specialty-based disparities in attitudes and practices persist, suggesting that ongoing efforts are needed to motivate physicians to recommend this vaccine to adolescents and to clarify how to integrate Tdap with other adolescent vaccinations.
2006年,免疫实践咨询委员会(ACIP)建议用破伤风类毒素、白喉类毒素和无细胞百日咳联合疫苗(Tdap)替代青少年破伤风和白喉类毒素(Td)加强疫苗。我们研究了儿科医生和家庭医生采纳这一建议的程度。
2007年1月至3月,对725名儿科医生和725名家庭医生的随机样本进行全国性邮寄调查。
总体回复率为60%。大多数受访者表示,他们通常会向首选接种年龄(11至12岁)的青少年推荐Tdap(87%),也会向13至18岁的青少年推荐“补种”Tdap(89%)。在双变量分析中,儿科医生专业、专业学会会员资格、诊所储备Tdap以及既往诊断青少年百日咳的经验与向青少年常规推荐Tdap有关。在同时对这些因素进行调整的多变量模型中,只有儿科医生专业(比值比[OR]=4.8,95%置信区间[CI]=2.5至9.3)和诊所储备Tdap(OR=14.5,95%CI=7.5至28.5)仍与常规推荐显著相关。儿科医生比家庭医生更有可能接受在接种Td后较短时间内接种Tdap,并与四价脑膜炎球菌结合疫苗(MCV4)同时接种。青少年就诊次数不足是青少年接种Tdap最常提到的主要障碍。
根据自我报告,我们的结果表明,大多数医生已采纳ACIP最近向青少年接种Tdap的建议。然而,基于专业的态度和做法差异仍然存在,这表明需要持续努力,促使医生向青少年推荐这种疫苗,并阐明如何将Tdap与其他青少年疫苗接种相结合。